Skip to main content

Table 1 Clinical and demographic data of study participants

From: Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics

   

Training Sample

Validation Sample

 

Healthy controls

ALS patients surviving

 

ALS patients surviving

 
  

p-value*

< 18 months

> 18 months

p-value

< 18 months

> 18 months

p-value

n

69

 

24

24

 

6

6

 

Gender (male/ female)

34/35

P = 0.22

17/7

13/11

P = .37

3/3

2/4

P = 1

Handedness (right/left)

64/5

P = .55

23/1

20/4

P = .35

5/1

5/1

P = 1

Age, years (means, SD**)

59.97 (9.9)

P = .17

63.18 (8)

61.76 (10.73)

P = .60

63.96 (8.03)

55.09 (8.82)

P = .09

Site of onset (bulbar/spinal)

  

8/16

10/14

P = .76

3/3

2/4

P = 1

Diagnostic delay, years (mean, SD)

  

1.2 (0.81)

1.05 (0.75)

P = .51

1.28 (1.1)

0.88 (0.3)

P = .43

Disease duration from symptom onset until scan, years (mean, SD)

  

2.17 (1.01)

2.32 (1.34)

P = .67

1.94 (1.44)

1.85 (0.54)

P = .89

ALSFRS-r (mean, SD)

  

34.48 (6.84)

37.38 (6.21)

P = .12

34.5 (8.34)

39.17 (4.17)

P = .25

King’s College Staging (1/ 2/ 3/ 4/ unavailable)

  

4/5/3/7/5

4/9/5/4/2

 

0/1/2/2/1

2/2/1/1/0

 

MITOS Staging (0 /1/ 2/ 3/ unavailable)

  

10/8/1/0/5

19/2/0/1/2

 

3/1/1/0/1

6/0/0/0/0

 

Survival from scan, years (mean, SD)

  

0.94 (0.32)

2.26 (1.11)

P < .01

0.92 (0.26)

2.62 (1.32)**

P < .05

  1. *healthy controls were compared to the training sample of 48 patients. **SD standard deviation